Stuart J. Wong
YOU?
Author Swipe
View article: Patterns of response in head and neck cancer subregions using daily Quantitative MRI from MR-guided radiation therapy
Patterns of response in head and neck cancer subregions using daily Quantitative MRI from MR-guided radiation therapy Open
In this exploratory study, qMRI detected spatial heterogeneity in HNSCC. These findings support its potential role in guiding biologically adaptive RT strategies.
View article: Efficacy and safety of one-time autologous tumor-infiltrating lymphocyte cell therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
Efficacy and safety of one-time autologous tumor-infiltrating lymphocyte cell therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma Open
Background Recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) has a high recurrence rate after first-line immunotherapy or chemoimmunotherapy. The presence of a high density of tumor-infiltrating lymphocytes (TILs) i…
View article: Phase 2 Study of Low-Dose Paclitaxel and Cisplatin in Combination With Split-Course Concomitant Twice-Daily Reirradiation in Recurrent Squamous Cell Carcinoma of the Head and Neck: Long-term Follow-up of NRG Oncology Radiation Therapy Oncology Group Protocol 9911
Phase 2 Study of Low-Dose Paclitaxel and Cisplatin in Combination With Split-Course Concomitant Twice-Daily Reirradiation in Recurrent Squamous Cell Carcinoma of the Head and Neck: Long-term Follow-up of NRG Oncology Radiation Therapy Oncology Group Protocol 9911 Open
Despite a high incidence of grade 5 toxicity, OS rates for this trial evaluating concurrent split course twice a day reirradiation with cisplatin and paclitaxel exceeded results seen historically with chemotherapy alone.
View article: Radiation therapy results in preferential tumor antigen-specific lymphodepletion in head and neck cancer
Radiation therapy results in preferential tumor antigen-specific lymphodepletion in head and neck cancer Open
Human Papillomavirus (HPV)-negative head and neck squamous cell carcinoma (HNSCC) remains a challenging malignancy, with radiotherapy, alone or combined with immune checkpoint inhibitors, often failing to achieve durable disease control. H…
View article: Quantitative magnetic resonance imaging responses in head and neck cancer patients treated with magnetic resonance-guided hypofractionated radiation therapy
Quantitative magnetic resonance imaging responses in head and neck cancer patients treated with magnetic resonance-guided hypofractionated radiation therapy Open
View article: Weight maintenance on cost‐effective antiobesity medications after 1 year of <scp>GLP‐1</scp> receptor agonist therapy: a real‐world study
Weight maintenance on cost‐effective antiobesity medications after 1 year of <span>GLP‐1</span> receptor agonist therapy: a real‐world study Open
Objective The high cost of novel glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) class agents often limits access and creates barriers to care. This real‐world study evaluated the efficacy of older‐generation generic antiobesity medica…
View article: Radiotherapy with cetuximab or durvalumab for locoregionally advanced head and neck cancer in patients with a contraindication to cisplatin (NRG-HN004): an open-label, multicentre, parallel-group, randomised, phase 2/3 trial
Radiotherapy with cetuximab or durvalumab for locoregionally advanced head and neck cancer in patients with a contraindication to cisplatin (NRG-HN004): an open-label, multicentre, parallel-group, randomised, phase 2/3 trial Open
US National Cancer Institute and AstraZeneca.
View article: 61 Insights into interferons (IFN)-myeloid cell crosstalk: an analysis of E3611 testing ipilimumab alone or in combination with IFN-α in advanced melanoma
61 Insights into interferons (IFN)-myeloid cell crosstalk: an analysis of E3611 testing ipilimumab alone or in combination with IFN-α in advanced melanoma Open
View article: 1480 Eseba-vec (HB-200) plus pembrolizumab as first-line treatment of recurrent/metastatic HPV16-positive head and neck cancer: updated results in PD-L1 CPS ≥20 patients
1480 Eseba-vec (HB-200) plus pembrolizumab as first-line treatment of recurrent/metastatic HPV16-positive head and neck cancer: updated results in PD-L1 CPS ≥20 patients Open
View article: Intensity-Modulated Reirradiation Therapy With Nivolumab in Recurrent or Second Primary Head and Neck Squamous Cell Carcinoma
Intensity-Modulated Reirradiation Therapy With Nivolumab in Recurrent or Second Primary Head and Neck Squamous Cell Carcinoma Open
Importance Intensity-modulated radiation therapy (IMRT) reirradiation of nonmetastatic recurrent or second primary head and neck squamous cell carcinoma (HNSCC) results in poor progression-free survival (PFS) and overall survival (OS). Obj…
View article: Type I interferon signaling promotes radioresistance in head and neck cancer
Type I interferon signaling promotes radioresistance in head and neck cancer Open
Despite the promise of concurrent radiotherapy (RT) and immunotherapy in head and neck cancer (HNC), multiple randomized trials of this combination have had disappointing results. To evaluate potential immunologic mechanisms of RT resistan…
View article: Corrigendum to Tumor-specific T cells in head and neck cancer have rescuable functionality and can be identified through single-cell co-culture
Corrigendum to Tumor-specific T cells in head and neck cancer have rescuable functionality and can be identified through single-cell co-culture Open
View article: Selpercatinib combination with the mitochondria-targeted antioxidant MitoQ effectively suppresses RET–mutant thyroid cancer
Selpercatinib combination with the mitochondria-targeted antioxidant MitoQ effectively suppresses RET–mutant thyroid cancer Open
View article: Tumor-specific T cells in head and neck cancer have rescuable functionality and can be identified through single-cell co-culture
Tumor-specific T cells in head and neck cancer have rescuable functionality and can be identified through single-cell co-culture Open
View article: 679 Characterization of tumor specific CD8+ T cell responses in patients with recurrent/metastatic HPV16-positive head and neck cancer receiving HB-200 monotherapy as second or later line treatment in a phase 1 study
679 Characterization of tumor specific CD8+ T cell responses in patients with recurrent/metastatic HPV16-positive head and neck cancer receiving HB-200 monotherapy as second or later line treatment in a phase 1 study Open
Background Prognosis is poor for patients with recurrent/metastatic (R/M) human papillomavirus (HPV) 16+ head and neck squamous cell carcinoma (HNSCC) after first-line standard of care therapy. HB-200 is comprised of an alternating sequenc…
View article: 921P HB-200 arenavirus-based immunotherapy plus pembrolizumab as a first-line treatment of patients with recurrent/metastatic HPV16 positive head and neck cancer
921P HB-200 arenavirus-based immunotherapy plus pembrolizumab as a first-line treatment of patients with recurrent/metastatic HPV16 positive head and neck cancer Open
View article: Differential Response in Quantitative MRI Parameters Detected in Head and Neck Cancer Patients Treated with Concurrent Immunotherapy during Hypo-Fractionated MR-gRT
Differential Response in Quantitative MRI Parameters Detected in Head and Neck Cancer Patients Treated with Concurrent Immunotherapy during Hypo-Fractionated MR-gRT Open
View article: Radiotherapy Plus Cisplatin With or Without Lapatinib for Non–Human Papillomavirus Head and Neck Carcinoma
Radiotherapy Plus Cisplatin With or Without Lapatinib for Non–Human Papillomavirus Head and Neck Carcinoma Open
Importance Patients with locally advanced non–human papillomavirus (HPV) head and neck cancer (HNC) carry an unfavorable prognosis. Chemoradiotherapy (CRT) with cisplatin or anti–epidermal growth factor receptor (EGFR) antibody improves ov…
View article: Photoactivated HPPH-Liposomal therapy for the treatment of HPV-Negative head and neck cancer
Photoactivated HPPH-Liposomal therapy for the treatment of HPV-Negative head and neck cancer Open
View article: Table S1, Table S2 from E3611—A Randomized Phase II Study of Ipilimumab at 3 or 10 mg/kg Alone or in Combination with High-Dose Interferon-α2b in Advanced Melanoma
Table S1, Table S2 from E3611—A Randomized Phase II Study of Ipilimumab at 3 or 10 mg/kg Alone or in Combination with High-Dose Interferon-α2b in Advanced Melanoma Open
Table S1- Tumor response by RECIST criteria. Table S2- Treatment details and reasons for discontinuation.
View article: Supplemental figure 1 from Profiling of 149 Salivary Duct Carcinomas, Carcinoma Ex Pleomorphic Adenomas, and Adenocarcinomas, Not Otherwise Specified Reveals Actionable Genomic Alterations
Supplemental figure 1 from Profiling of 149 Salivary Duct Carcinomas, Carcinoma Ex Pleomorphic Adenomas, and Adenocarcinomas, Not Otherwise Specified Reveals Actionable Genomic Alterations Open
Photomicrographs of two ETV6-NTRK3 fusion cases.
View article: Supplemental figure legend from Profiling of 149 Salivary Duct Carcinomas, Carcinoma Ex Pleomorphic Adenomas, and Adenocarcinomas, Not Otherwise Specified Reveals Actionable Genomic Alterations
Supplemental figure legend from Profiling of 149 Salivary Duct Carcinomas, Carcinoma Ex Pleomorphic Adenomas, and Adenocarcinomas, Not Otherwise Specified Reveals Actionable Genomic Alterations Open
This is the legend for the supplemental figure
View article: Table S1, Table S2 from E3611—A Randomized Phase II Study of Ipilimumab at 3 or 10 mg/kg Alone or in Combination with High-Dose Interferon-α2b in Advanced Melanoma
Table S1, Table S2 from E3611—A Randomized Phase II Study of Ipilimumab at 3 or 10 mg/kg Alone or in Combination with High-Dose Interferon-α2b in Advanced Melanoma Open
Table S1- Tumor response by RECIST criteria. Table S2- Treatment details and reasons for discontinuation.
View article: Data from E3611—A Randomized Phase II Study of Ipilimumab at 3 or 10 mg/kg Alone or in Combination with High-Dose Interferon-α2b in Advanced Melanoma
Data from E3611—A Randomized Phase II Study of Ipilimumab at 3 or 10 mg/kg Alone or in Combination with High-Dose Interferon-α2b in Advanced Melanoma Open
Purpose:Interferon-α favors a Th1 shift in immunity, and combining with ipilimumab (ipi) at 3 or 10 mg/kg may downregulate CTLA4-mediated suppressive effects, leading to more durable antitumor immune responses. A study of tremelimumab and …
View article: Data from Nomogram to Predict the Benefit of Intensive Treatment for Locoregionally Advanced Head and Neck Cancer
Data from Nomogram to Predict the Benefit of Intensive Treatment for Locoregionally Advanced Head and Neck Cancer Open
Purpose:Previous studies indicate that the benefit of therapy depends on patients' risk for cancer recurrence relative to noncancer mortality (ω ratio). We sought to test the hypothesis that patients with head and neck cancer (HNC) with a …
View article: Supplemental table 1 from Profiling of 149 Salivary Duct Carcinomas, Carcinoma Ex Pleomorphic Adenomas, and Adenocarcinomas, Not Otherwise Specified Reveals Actionable Genomic Alterations
Supplemental table 1 from Profiling of 149 Salivary Duct Carcinomas, Carcinoma Ex Pleomorphic Adenomas, and Adenocarcinomas, Not Otherwise Specified Reveals Actionable Genomic Alterations Open
Detailed genetic results
View article: Data from Profiling of 149 Salivary Duct Carcinomas, Carcinoma Ex Pleomorphic Adenomas, and Adenocarcinomas, Not Otherwise Specified Reveals Actionable Genomic Alterations
Data from Profiling of 149 Salivary Duct Carcinomas, Carcinoma Ex Pleomorphic Adenomas, and Adenocarcinomas, Not Otherwise Specified Reveals Actionable Genomic Alterations Open
Purpose: We sought to identify genomic alterations (GA) in salivary gland adenocarcinomas, not otherwise specified (NOS), salivary duct carcinomas (SDC), carcinoma ex pleomorphic adenoma (ca ex PA), and salivary carcinoma, NOS.Ex…
View article: Supplemental methods from Profiling of 149 Salivary Duct Carcinomas, Carcinoma Ex Pleomorphic Adenomas, and Adenocarcinomas, Not Otherwise Specified Reveals Actionable Genomic Alterations
Supplemental methods from Profiling of 149 Salivary Duct Carcinomas, Carcinoma Ex Pleomorphic Adenomas, and Adenocarcinomas, Not Otherwise Specified Reveals Actionable Genomic Alterations Open
Expanded methods for the study.
View article: Data from Profiling of 149 Salivary Duct Carcinomas, Carcinoma Ex Pleomorphic Adenomas, and Adenocarcinomas, Not Otherwise Specified Reveals Actionable Genomic Alterations
Data from Profiling of 149 Salivary Duct Carcinomas, Carcinoma Ex Pleomorphic Adenomas, and Adenocarcinomas, Not Otherwise Specified Reveals Actionable Genomic Alterations Open
Purpose: We sought to identify genomic alterations (GA) in salivary gland adenocarcinomas, not otherwise specified (NOS), salivary duct carcinomas (SDC), carcinoma ex pleomorphic adenoma (ca ex PA), and salivary carcinoma, NOS.Ex…
View article: Supplementary Data from Nomogram to Predict the Benefit of Intensive Treatment for Locoregionally Advanced Head and Neck Cancer
Supplementary Data from Nomogram to Predict the Benefit of Intensive Treatment for Locoregionally Advanced Head and Neck Cancer Open
Supplementary Data: Tables S1-S2; Figures S1-S4